Cargando…

Effect of Sodium-Glucose Cotransport Inhibition on Polycystic Kidney Disease Progression in PCK Rats

The sodium-glucose-cotransporter-2 (SGLT2) inhibitor dapagliflozin (DAPA) induces glucosuria and osmotic diuresis via inhibition of renal glucose reabsorption. Since increased diuresis retards the progression of polycystic kidney disease (PKD), we investigated the effect of DAPA in the PCK rat model...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kapoor, Sarika, Rodriguez, Daniel, Riwanto, Meliana, Edenhofer, Ilka, Segerer, Stephan, Mitchell, Katharyn, Wüthrich, Rudolf P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416041/ https://www.ncbi.nlm.nih.gov/pubmed/25927597 http://dx.doi.org/10.1371/journal.pone.0125603

Ejemplares similares

Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease
por: Riwanto, Meliana, et al.
Publicado: (2016)

Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction
por: Afsar, Baris, et al.
Publicado: (2022)

The Role of T Cell Costimulation via DNAM-1 in Kidney Transplantation
por: Kraus, Anna K., et al.
Publicado: (2016)

Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease
por: Blazer-Yost, Bonnie L., et al.
Publicado: (2010)

Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease
por: Oto, Ozgur A., et al.
Publicado: (2023)

Sodium-glucose cotransporter-2 inhibitor use in kidney transplant recipients
por: Ramakrishnan, Pavithra, et al.
Publicado: (2023)

Collagen-driven remodeling of the intrahepatic duct wall in the PCK rat model of polycystic kidney disease-Caroli syndrome
por: Narayan, Rithika, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
por: Osorio, Horacio, et al.
Publicado: (2012)

Roles of Sodium-Glucose Cotransporter 2 of Mesangial Cells in Diabetic Kidney Disease
por: Wakisaka, Masanori, et al.
Publicado: (2021)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease
por: Kato, Shingo, et al.
Publicado: (2022)

Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors
por: Pruett, Jacob E., et al.
Publicado: (2023)

Impaired epithelial Na(+) channels activity contributes to cystogenesis and development of autosomal recessive polycystic kidney disease in PCK rats
por: Pavlov, Tengis S., et al.
Publicado: (2014)

Sodium–Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?
por: Post, Adrian, et al.
Publicado: (2020)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

The Application of Sodium-Glucose Cotransporter 2 Inhibitors to Chronic Kidney Disease Stage 4
por: Koguchi, Ayako, et al.
Publicado: (2017)

Sodium-glucose cotransporter 2 inhibitors for diabetic kidney disease: a primer for deprescribing
por: Li, Jiahua, et al.
Publicado: (2019)

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease
por: Heerspink, Hiddo J L, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease
por: Shivakumar, Oshini, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?
por: Dekkers, Claire C J, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
por: Górriz, Jose Luis, et al.
Publicado: (2020)

Metabolomic profiling in kidney cells treated with a sodium glucose-cotransporter 2 inhibitor
por: Jo, Hyung Ah, et al.
Publicado: (2023)

Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease
por: Kugita, Masanori, et al.
Publicado: (2017)

A Meta-Analysis of the Effect of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic Parameters in Patients With Polycystic Ovary Syndrome
por: Sinha, Binayak, et al.
Publicado: (2022)

Perioperative Implication of Sodium-glucose Cotransporter-2 Inhibitor in a Patient Following Major Surgery
por: Vadi, Sonali, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Inhibition of Sodium Glucose Cotransporters Improves Cardiac Performance
por: García-Ropero, Álvaro, et al.
Publicado: (2019)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Sodium–glucose cotransporters: Functional properties and pharmaceutical potential
por: Sano, Ryuhei, et al.
Publicado: (2020)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition
por: Poudel, Resham Raj
Publicado: (2013)

The Spectrum of Podoplanin Expression in Encapsulating Peritoneal Sclerosis
por: Braun, Niko, et al.
Publicado: (2012)

A new era of diabetic kidney disease treatment with sodium–glucose cotransporter‐2 inhibitors
por: Kume, Shinji, et al.
Publicado: (2022)

Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Cardiovascular Disease and Chronic Kidney Disease
por: Rastogi, Anjay, et al.
Publicado: (2023)

Searching in the maze: sodium–glucose cotransporter-2 inhibitors in kidney transplant recipients to improve survival
por: Oliveras, Laia, et al.
Publicado: (2023)

From Kidney Protection to Stroke Prevention: The Potential Role of Sodium Glucose Cotransporter-2 Inhibitors
por: Hsieh, Cheng-Yang, et al.
Publicado: (2022)

Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease
por: Zhang, Yanling, et al.
Publicado: (2016)

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6r5fbbtl80oenans19u44q5mjh